SINOVAC-BIOTECH
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud Pública, ISP) approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine (ancestral, Delta and Omicron variants) on August 31st. The clinical trial will evaluate the immunogenicity and safety of one booster dose of the two candidate vaccines in adults who had received two booster doses of CoronaVac®, mRNA, or adenovirus vector COVID-19 vaccine. This study is the world's first study researching multivalent inactivated COVID-19 vaccine.
In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited. Participants belonging to the heterologous scheme are individuals who had received two CoronaVac® doses, and two boosters of mRNA-based or viral vector-based vaccines, while participants of the homologous scheme had received four doses of CoronaVac®. Individuals from the heterologous scheme will randomly receive a booster dose with the Omicron, Trivalent, or CoronaVac® vaccines, while individuals from the homogeneous group will randomly receive a booster dose of the Omicron or the trivalent vaccines.
Mr. Weidong Yin, the Chairman, President, and CEO of SINOVAC said, “SINOVAC has made great progress collaborating with global partners in the development and manufacturing of the COVID-19 vaccine. We are proud of the fact that CoronaVac® can protect individuals as young as 6 months of age and this clinical approval will allow even better vaccine protection.”
About SINOVAC
Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis. Its COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. Its Healive®, hepatitis A vaccine, passed WHO prequalification requirements in 2017. Its EV71 vaccine, Inlive®, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) was prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005511/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis and Ottawa Senators Renew Partnership, Uniting National Capital Region26.6.2025 20:32:00 CEST | Press release
Bold partnership focuses on elevating community impact and brand presence Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, is proud to announce a renewed three-year partnership with the Ottawa Senators and their AHL affiliate, the Belleville Senators. This collaboration is designed to amplify Kinaxis’ brand visibility, deepen community roots, and create unforgettable experiences for customers, prospects, and employees. As two proud Ottawa-based organizations, Kinaxis and the Senators will come together again to celebrate local talent, foster youth development, and drive meaningful community engagement. The partnership will also spotlight the Kinaxis brand across high-visibility platforms—including center ice at Canadian Tire Centre, LED rings, and digital dashboards during home and away games—ensuring a powerful presence throughout the NHL season. “At Kinaxis, we believe in the power of community and the importance of showing up where it matters most,” said
CB Insights Unveils Industry's First AI Agent Workforce for M&A, Partnerships, Competitive Intelligence, Deal Sourcing, GTM, and More26.6.2025 18:49:00 CEST | Press release
Purpose-built agents work around the clock to deliver external intelligence that transforms how enterprises make strategic decisions CB Insights, the leading provider of predictive market intelligence, today announced the launch of its Team of Agents – the industry's first comprehensive AI agent workforce designed specifically to enable business leaders with always-on market intelligence for strategic decision-making. CB Insights’ growing team of agents starts with 11 specialized agents that work continuously to uncover insights, translate proprietary data into action, and accelerate smart decisions by providing the external intelligence layer that enterprises need to compete effectively across business development, investments, partnerships, GTM, and competitive intelligence. While generic AI assistants struggle with business context and lack reliable external data, CB Insights' Team of Agents delivers validated intelligence and data science on over 10 million companies and 1,500 tech
Pure Lithium and CEO Emilie Bodoin Recognized for Innovations at Reuters Global Energy Transition Awards26.6.2025 18:27:00 CEST | Press release
Pure Lithium Corporation, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce that it has won the 2025 Reuters Global Energy Transition award for R&D Achievement. The award, presented at a June 24th ceremony in New York, recognizes research and development projects that promote a science-oriented energy transition while yielding promising potential and achievement. Pure Lithium has developed lithium metal batteries with double the energy density of lithium-ion cells and an industry-leading cycle life. By prioritizing research and development, the company achieved step-change advancements in battery technology and has built a strong portfolio of 119 patents and applications. “We’re thrilled to be selected for this prestigious award, which recognizes the hard work, dedication and creativity of our world-class team,” said Pure Lithium Founder and CEO Emilie Bodoin. “We know that commercializing a new chemistry requires a delicate balance of
Ant Group Launches AI Healthcare App AQ Amid Push into Healthcare Sector26.6.2025 16:41:00 CEST | Press release
Digital leader aims to capture rising cross-generational demand for public and private healthcare services amid demographic shift and urbanization trends.The launch of AQ enhances Ant Group’s comprehensive suite of AI solutions for healthcare, enabling medical institutions and doctors to offer more efficient, accessible, and personalized services. Ant Group today launched its AI healthcare app, AQ, to accelerate the company’s entry into the healthcare sector. The app helps users manage their daily healthcare needs with over 100 AI-powered services, including doctor recommendations, medical report analysis, and personalized medical advice. It also connects users to digital services from over 5,000 hospitals and nearly 1 million doctors across China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250626728870/en/ Ant Group launched the AI healthcare app AQ to accelerate its entry into the healthcare sector By around 2035, over
Wasabi Technologies Becomes Official Cloud Storage Partner and Front-of-Jersey Sponsor of USA Rugby26.6.2025 16:00:00 CEST | Press release
USA Rugby partnership marks the latest addition to Wasabi’s robust sports sponsorship portfolio Wasabi Technologies, the hot cloud storage company, today announced it has strengthened its sports sponsorship program as the Official Cloud Storage Partner of USA Rugby. This milestone partnership unites two organizations committed to rapid growth, excellence, and technology innovation. Wasabi is purpose-built for media-rich industries like sports and entertainment and offers simple, fast, and predictable cloud storage for organizations with growing content archives. USA Rugby now stands alongside Wasabi’s compelling sponsorship portfolio of teams unlocking the power of their data, including iconic organizations, like the Boston Red Sox and Liverpool Football Club. “With digital transformation being top of mind for all sports organizations, we can’t think of a better partner than Wasabi to innovate alongside,” said USA Rugby CEO, Bill Goren. “Wasabi has established itself as a true industry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom